SCHEMBL4048180

SCHEMBL4048180

[c]1n[nH]c(-c2ccnc(-c3ccccc3)c2)n1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 6/20 0.47
ASIC3 Q9UHC3 1/20 0.46
PIM1 P11309 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CDK1 P06493 1/20 0.40
MAPKAPK2 P49137 1/20 0.40
MAPKAPK3 Q16644 1/20 0.40
MAPKAPK5 Q8IW41 1/20 0.40
MKNK1 Q9BUB5 1/20 0.40
USP30 Q70CQ3 1/20 0.37
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
POLB P06746 1/20 0.36
SMO Q99835 2/20 0.36
FHIT P49789 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043825 0.89 TGFBR1 (0.43) TGFBR1ASIC3PIM1CYP1A2CYP3A4
SCHEMBL796065 0.80 NR1H2 (0.42) CYP1A2RAB9ANPC1POLB
SCHEMBL4048514 0.80 GP6 (0.40) CYP1A2CYP3A4RAB9ANPC1POLB
SCHEMBL4047399 0.79 ASIC3 (0.47) ASIC3CYP1A2RAB9ANPC1SMN1; SMN2
SCHEMBL4051736 0.77 NR1H2 (0.39) CYP1A2RAB9ANPC1POLBGSK3B
SCHEMBL21692157 0.76 ASIC3 (0.65) TGFBR1ASIC3PIM1CDK1MAPKAPK2
SCHEMBL4044973 0.76 ASIC3 (0.45) TGFBR1ASIC3PIM1CYP1A2CYP3A4
SCHEMBL4046873 0.76 KMT2A (0.43) RAB9ANPC1SMN1; SMN2POLBSMO
SCHEMBL912763 0.74 ASIC3 (0.63) TGFBR1ASIC3PIM1CDK1MAPKAPK2
SCHEMBL29578028 0.74 ASIC3 (0.63) TGFBR1ASIC3PIM1CDK1MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589096-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US disclosed
EP-1566384-B1 NOVEL AZOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2009-06-17 EP disclosed
US-20080188507-A1 Novel azole derivatives MSD K.K. (JP) 2008-08-07 US disclosed
US-7365079-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-29 US disclosed
US-20060111380-A1 Novel azole derivatives MSD K.K. (JP) 2006-05-25 US disclosed
EP-1566384-A1 NOVEL AZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188507-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R TGFBR1 1025/4885ASIC3 2935/4885PIM1 3522/4885
US-20060111380-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R TGFBR1 1242/4885ASIC3 2996/4885PIM1 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.